The rationale behind grafting haploidentical hematopoietic stem cells

References

• Hahn T, McCarthy PL, Hassebroek A, et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol. 2013;31(19):2437–2449. doi:10.1200/JCO.2012.46.6193
   PubMed Web of Science ®Google Scholar
• Giralt SA, Arora M, Goldman JM, et al. Impact of imatinib therapy on the use of allogeneic hematopoietic progenitor cell transplantation for the treatment of chronic myelogenous leukemia. Brit J Hem. 2007;137:461–467. doi:10.1111/j.1365-2141.2007.06582.x
   PubMed Web of Science ®Google Scholar
• Gribben JG. How and when I do allogeneic transplant in CLL. Blood. 2018 Jul 5;132(1):31–39. doi:10.1182/blood-2018-01-785998
   PubMed Web of Science ®Google Scholar
• Muffly L, Pasquini MC, Martens M, et al. Increasing use of allogeneic cell transplantation in patients age 70 years and older in the United States. Blood. 2017;130(9):1156–1164. doi:10.1182/blood-2017-03-772368
   PubMed Web of Science ®Google Scholar
• Jani CT, Ahmed A, Singh H, et al. Burden of AML, 1990-2019: Estimates from the global burden of disease study. Jco glob oncol. 2023;9:e2300229. doi:10.1200/GO.23.00229
   PubMedGoogle Scholar
• Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of acute myeloid leukemia in adults: 2022 recommendations from an International Expert Panel, on behalf of the European LeukemiaNet. Blood. 2022;140(12):1345–1377. doi:10.1182/blood.2022016867
   PubMed Web of Science ®Google Scholar
• Sorror ML, Storb R, Sandmaier BM, et al. Comorbidity-Age Index: a clinical measure of biological age prior to allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014;32(29):3249–3256. doi:10.1200/JCO.2013.53.8157
   PubMed Web of Science ®Google Scholar
• Sorror ML, Martin PJ, Storb RF, et al. Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. Blood. 2014;124(2):287–295. doi:10.1182/blood-2014-01-550566
   PubMed Web of Science ®Google Scholar
• Bolon YT, Atshan R, Allbee-Johnson X, et al. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides, 2022.
   Google Scholar
• https://wmda.info. (Accessed 12/28/23).
   Google Scholar
• Reisner Y, Kapoor N, Kirkpatrick D, et al. Transplantation for acute leukaemia with HLA-A and B non-identical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet. 1981;2:327–331. doi:10.1016/S0140-6736(81)90647-4
   PubMed Web of Science ®Google Scholar
• Antin JH, Bierer BE, Smith BR, et al. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood. 1991;78(8):2139–2149. doi:10.1182/blood.V78.8.2139.2139
   PubMed Web of Science ®Google Scholar
• Soiffer RJ, Murray C, Mauch P, et al. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. J Clin Oncol. 1992;10(7):1191–1200. doi:10.1200/JCO.1992.10.7.1191
   PubMed Web of Science ®Google Scholar
• Champlin RE, Passweg JR, Zhang MJ, et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood. 2000;95(12):3996–4003.
   PubMed Web of Science ®Google Scholar
• Soiffer RJ, Mauch P, Tarbell NJ, et al. Total lymphoid irradiation to prevent graft rejection in recipients of HLA non-identical T cell-depleted allogeneic marrow. Bone Marrow Transplant. 1991;7(1):23–33.
   PubMed Web of Science ®Google Scholar
• Apperley JF, Mauro FR, Goldman JM, et al. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect. Br J Haematol. 1988;69(2):239–245. doi:10.1111/j.1365-2141.1988.tb07628.x
   PubMed Web of Science ®Google Scholar
• Bjorkman PJ, Saper MA, Samraoui B, et al. Structure of the human class I histocompatibility antigen, HLA-A2. Nature. 1987;329(6139):506–512. doi:10.1038/329506a0
   PubMed Web of Science ®Google Scholar
• Bjorkman PJ, Saper MA, Samraoui B, et al. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature. 1987;329(6139):512–518. doi:10.1038/329512a0
   PubMed Web of Science ®Google Scholar
• Buckley RH, Schiff SE, Sampson HA, et al. Development of immunity in human severe primary T cell deficiency following haploidentical bone marrow stem cell transplantation. J Immunol. 1986;136:2398–2407. doi:10.4049/jimmunol.136.7.2398
   PubMed Web of Science ®Google Scholar
• Friedrich W, Goldmann SF, Vetter U, et al. Immunoreconstitution in severe combined immunodeficiency after transplantation of HLA haploidentical, T-cell-depleted bone marrow. Lancet. 1984;1:761–765. doi:10.1016/S0140-6736(84)91277-7
   PubMed Web of Science ®Google Scholar
• Fischer A, Durandy A, de Villartay JP, et al. HLA-haploidentical bone marrow transplantation for severe combined immune deficiency using E-rosette fractionation and cyclosporine. Blood. 1986;67:444–449. doi:10.1182/blood.V67.2.444.444
   PubMed Web of Science ®Google Scholar
• Gale RP. Reisner Y: Graft rejection and graft-versus-host disease: mirror images. Lancet. 1986;1:1468–1470. doi:10.1016/S0140-6736(86)91503-5
   PubMed Web of Science ®Google Scholar
• Kernan NA, Flomenberg N, Dupont B. O’Reilly RJ: Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia. Identification of host-derived antidonor allocytotoxic T lymphocytes. Transplantation. 1987;43:842–847. doi:10.1097/00007890-198743060-00014
   PubMed Web of Science ®Google Scholar
• Bierer BE, Emerson SG, Antin JH, et al. Regulation of cytotoxic T lymphocyte-mediated graft rejection following bone marrow transplantation. Transplantation. 1988;46:835–839. doi:10.1097/00007890-198812000-00009
   PubMed Web of Science ®Google Scholar
• Araten DJ, Lawton T, Ferrara JM, et al. In vitro alloreactivity against host antigens in adult HLA mismatched bone marrow transplant recipient despite in vivo host tolerance. Transplantation. 1993;55:76–82. doi:10.1097/00007890-199301000-00015
   PubMed Web of Science ®Google Scholar
• Schwartz E, Lapidot T, Gozes D, et al. Abrogation of bone marrow allograft resistance in mice by increased total body irradiation correlates with eradication of host clonable T-cells and alloreactive cytotoxic precursors. J Immunol. 1987;138:460–465. doi:10.4049/jimmunol.138.2.460
   PubMed Web of Science ®Google Scholar
• Butturini A, Seeger RC, Gale RP. Recipient immune-competent T lymphocytes can survive intensive conditioning for bone marrow transplantation. Blood. 1986;68:954–956. doi:10.1182/blood.V68.4.954.954
   PubMed Web of Science ®Google Scholar
• Lapidot T, Terenzi A, Singer TS, et al. Enhancement by dimethyl myleran of donor type chimerism in murine recipients of bone marrow allografts. Blood. 1989;73:2025–2032. doi:10.1182/blood.V73.7.2025.2025
   PubMed Web of Science ®Google Scholar
• Soderling CC, Song CW, Blazer BR, et al. Correlation between conditioning and engraftment in recipients of MHC mismatched T cell-depleted murine bone marrow transplants. J Immunol. 1985 Aug;135(2):941–946. doi:10.4049/jimmunol.135.2.941
   PubMed Web of Science ®Google Scholar
• Morrison SJ, Uchida N, Weissman IL. The biology of hematopoietic stem cells. Annu Rev Cell Dev Biol. 1995;11:35–71. doi:10.1146/annurev.cb.11.110195.000343
   PubMed Web of Science ®Google Scholar
• Baum CM, Weissman IL, Tsukamoto AS, et al. Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci USA. 1992;89(7):2804–2808. doi:10.1073/pnas.89.7.2804
   PubMed Web of Science ®Google Scholar
• Uchida N, Aguila HL, Fleming WH, et al. Rapid and sustained hematopoietic recovery in lethally irradiated mice transplanted with purified Thy-1.1lo Lin-Sca-1 + hematopoietic stem cells. Blood. 1994;83(12):3758–3779. doi:10.1182/blood.V83.12.3758.3758
   PubMed Web of Science ®Google Scholar
• Quesenberry PJ, Wen S, Goldberg LR, et al. The universal stem cell. Leukemia. 2022;36:2784–2792. doi:10.1038/s41375-022-01715-w
   PubMedGoogle Scholar
• Rao SS, Peters SO, Crittenden RB, et al. Stem cell transplantation in the normal nonmyeloablated host: relationship between cell dose, schedule, and engraftment. Exp Hematol. 1997 Feb;25(2):114–121.
   PubMed Web of Science ®Google Scholar
• Quesenberry PJ, Becker P, Stewart FM. Phenotype of the engrafting stem cell in mice. Stem Cells. 1998;16(Suppl 1):33–35.
   PubMedGoogle Scholar
• Jones HM, Jones SA, Watts MJ, et al. Development of a simplified single-apheresis approach for peripheral-blood progenitor-cell transplantation in previously treated patients with lymphoma. J Clin Oncol. 1994 Aug;12(8):1693–1702. doi:10.1200/JCO.1994.12.8.1693
   PubMed Web of Science ®Google Scholar
• Aversa F, Terenzi A, Tabilio A, et al. Addition of PBPCs to the marrow inoculum allows engraftment of mismatched T cell-depleted transplants for acute leukemia. Bone Marrow Transplant. 1996;17(Suppl 2):S58–S61.
   PubMedGoogle Scholar
• Reisner Y, Bachar-Lustig E, Li HW, et al. The role of megadose CD34 + progenitor cells in the treatment of leukemia patients without a matched donor and in tolerance induction for organ transplantation. Ann N Y Acad Sci. 1999;872:336–348. doi:10.1111/j.1749-6632.1999.tb08478.x
   PubMed Web of Science ®Google Scholar
• Reisner Y, Martelli MF. Tolerance induction by ‘megadose’ transplants of CD34 + stem cells: a new option for leukemia patients without an HLA-matched donor. Curr Opin Immunol. 2000 Oct;12(5):536–541. doi:10.1016/S0952-7915(00)00135-7
   PubMed Web of Science ®Google Scholar
• Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004;351:2265–2275. doi:10.1056/NEJMoa041276
   PubMed Web of Science ®Google Scholar
• Devine SM, Carter S, Soiffer RJ, et al. Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. Biol Blood Marrow Transplant. 2011 Sep;17(9):1343–1351. doi:10.1016/j.bbmt.2011.02.002
   PubMed Web of Science ®Google Scholar
• Keever-Taylor CA, Devine SM, Soiffer RJ, et al. Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303. Biol Blood Marrow Transplant. 2012;18(5):690–697. doi:10.1016/j.bbmt.2011.08.017
   PubMed Web of Science ®Google Scholar
• Solomon SR, Mielke S, Savani B, et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood. 2005 Aug 1;106(3):1123–1129. doi:10.1182/blood-2005-01-0393
   PubMed Web of Science ®Google Scholar
• Chao NJ, Snyder DS, Jain M, et al. Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. Biol Blood Marrow Transplant. 2000;6(3):254–261. doi:10.1016/S1083-8791(00)70007-3
   PubMed Web of Science ®Google Scholar
• Anasetti C, Logan BR, Lee SJ, et al. Peripheral blood stem cells versus bone marrow from unrelated donors: Results of Blood and Marrow Transplant Clinical Trials Network protocol 201, a phase III, prospective, randomized trial. N Engl J Med. 2012;367(16):1487–1496. doi:10.1056/NEJMoa1203517
   PubMed Web of Science ®Google Scholar
• Anasetti C, Beatty PG, Storb R, et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol. 1990;29(2):79–91. doi:10.1016/0198-8859(90)90071-V
   PubMed Web of Science ®Google Scholar
• Rimando J, McCurdy SR, Luznik L. How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond. Blood. 2023;141(1):49–59. doi:10.1182/blood.2021015129
   PubMed Web of Science ®Google Scholar
• Mariotti J, Raiola AM, Evangelista A, et al. Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide. Bone Marrow Transplant. 2022;57(12):1758–1764. doi:10.1038/s41409-022-01565-1
   PubMed Web of Science ®Google Scholar
• Yang F, Long N, Anekpuritanang T, et al. Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML. Blood. 2022;139(8):1208–1221. doi:10.1182/blood.2021011354
   PubMed Web of Science ®Google Scholar
• Shaw BE, Logan BR, Spellman SR, et al. Development of an unrelated donor selection score predictive of survival after HCT: donor age matters most. Biol Blood Marrow Transplant. 2018;24:1049–1056. doi:10.1016/j.bbmt.2018.02.006
   PubMed Web of Science ®Google Scholar
• Ruiz-Argüelles GJ, Seber A, Ruiz-Delgado GJ. Conducting hematopoietic stem cell transplantation in low and middle income countries. Hematology. 2022;27(1):809–812. doi:10.1080/16078454.2022.2105513
   PubMed Web of Science ®Google Scholar
• Maziarz RT, Devine S, Garrison LP, et al. Estimating the lifetime medical cost burden of an allogeneic hematopoietic cell transplantation patient. Transplant Cell Ther. 2023;29(10):637.e1–637.e9. doi:10.1016/j.jtct.2023.06.013
   PubMedGoogle Scholar
• Vago L, Perna SK, Zanussi M, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med. 2009;361:478–488. doi:10.1056/NEJMoa0811036
   PubMed Web of Science ®Google Scholar
• Leotta S, Condorelli A, Sciortino R, et al. Prevention and treatment of acute myeloid leukemia relapse after hematopoietic stem cell transplantation: The state of the Art and future perspectives. J Clin Med. 2022 Jan;11(1):253. doi:10.3390/jcm11010253
   PubMed Web of Science ®Google Scholar
• Patriarca F, Sperotto A, Lorentino F, et al. Donor lymphocyte infusions after allogeneic stem cell transplantation in acute leukemia: A survey from the gruppo italiano trapianto midollo osseo (GITMO). Front. Oncol. 2020;10:572918. doi:10.3389/fonc.2020.572918
   PubMed Web of Science ®Google Scholar